Figures computed from official regulatory filings — .
Analysttarget 2.12 USD (+1293%) · consensus 4.33/5 · 2 buy · 1 hold · 0 sell
Ownershipinsiders 11.32% · institutions 3.9% · short 9.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vivos Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
17 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Huntsman Ronald Kirktrack record | OtherD (derivative) | $50K | SEC |
| Huntsman Ronald Kirktrack record | Other | $50K | SEC |
| JOHNSON GREGG C | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SOKOLOW LEONARD Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Amman Bradford K. | AwardD (derivative) | $61.5K | SEC |
| Amman Bradford K. | Award | $102.5K | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $1.6M | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $1.1M | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $500K | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $2.4M | First in 12mo | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $576.1K | First in 12mo | SEC |
| Skaff Michael Ctrack record | Buy | $1.4M | conv 66First in 12mo | SEC |
| Skaff Michael Ctrack record | BuyD (derivative) | $2.4M | First in 12mo | SEC |
| Skaff Michael Ctrack record | Buy | $413.9K | conv 57First in 12mo | SEC |
| Amman Bradford K. | AwardD (derivative) | $394.8K | SEC |
| Huntsman Ronald Kirktrack record | AwardD (derivative) | $832.7K | SEC |
| Huntsman Ronald Kirktrack record | AwardD (derivative) | $47.6K | SEC |
| THOMPSON MATTHEW | AwardD (derivative) | $9.5K | SEC |
| Amman Bradford K. | AwardD (derivative) | $35.7K | SEC |
| Lindsay Mark F. | AwardD (derivative) | $9.5K | SEC |
| Krammer Anja B | AwardD (derivative) | $9.5K | SEC |
| SOKOLOW LEONARD Jtrack record | AwardD (derivative) | $9.5K | SEC |
| Green Ralph Elias | AwardD (derivative) | $9.5K | SEC |
| Huntsman Ronald Kirktrack record | Buy | $10.5 | conv 17Unusual size | SEC |
| Huntsman Ronald Kirktrack record | Buy | $2.7K | conv 20 | SEC |